Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients
Authors:
- Dirk R.J. KuypersDKDirk R.J. Kuypers
- Henriette de LoorHLHenriette de Loor
- Maarten NaesensMNMaarten Naesens
- Tamara CoopmansTCTamara Coopmans
- Hylke de JongeHJHylke de Jonge
- 1 December 2014
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 24 (12) , 597-606
Abstract
In a cohort of 298 de-novo renal recipients treated with a standard tacrolimus loading dose of 0.2 mg/kg, the combined effects of the CYP3A5*1, POR*28, and CYP3A4*22 genotypes on early tacrolimus exposure (C0), dose requirements, and achievement of the therapeutic target, C0, were examined. The incidence of clinical events (e.g. acute rejection, diabetes mellitus) was compared between genotypes. Fast metabolizers (CYP3A5*1/POR*28T carriers) had two-fold to three-fold higher tacrolimus dose requirements compared with slow metabolizers (CYP3A5*3/*3/CYP3A4*22 carriers) and needed significantly more time to achieve the target tacrolimus C0 of a minimum 10 ng/ml (3.3±1.7 vs. 1.34±0.75 days; P<0.0001). No differences in acute rejection incidence and time to first rejection were observed. Slow metabolizers more frequently had tacrolimus C0 above the target range early after transplantation (70 vs. 13% on day 3); however, this did not translate into a higher incidence of post-transplantation diabetes mellitus or graft dysfunction. Multivariate analyses identified the CYP3A5*1/POR*28/CYP3A4*22 genotype combination as the single strongest determinant of tacrolimus dose requirements throughout the first year, explaining between 24-40% of its variability, whereas recipient age, hematocrit, and delayed graft function were additional nongenetic determinants of tacrolimus dose. Combining the CYP3A5*1, POR*28 and CYP3A4*22 genotypes allows partial differentiation of early tacrolimus dose requirements and the time to reach therapeutic target concentrations after transplantation, but without obvious clinical implications. Larger prospective studies need to address the clinical relevance of early combined genotype-based tacrolimus dosing in de-novo renal recipients.Keywords
This publication has 30 references indexed in Scilit:
- The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipientsEuropean Journal of Clinical Pharmacology, 2014
- Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal TransplantationCPT: Pharmacometrics & Systems Pharmacology, 2014
- The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ TransplantationClinical Pharmacokinetics, 2013
- A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patientsPharmacogenetics and Genomics, 2013
- From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantationInternational Journal of Pharmaceutics, 2013
- The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomesThe Journal of Toxicological Sciences, 2013
- A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant RecipientsClinical Chemistry, 2011
- Effect of a New FunctionalCYP3A4Polymorphism on Calcineurin Inhibitors‘ Dose Requirements and Trough Blood Levels in Stable Renal Transplant PatientsPharmacogenomics, 2011
- Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant ConsortiumTransplantation, 2011
- Genetic contribution to variable human CYP3A-mediated metabolismAdvanced Drug Delivery Reviews, 2002